ストックスクリーナーアプリを入手
7.14
1.79%
-0.13
プレマーケット:
7.21
0.07
+0.98%
前日終値:
$7.27
開ける：
$7.28
24時間の取引高:
3.16M
Relative Volume:
0.57
時価総額：
$1.86B
収益：
$6.28B
当期純損益:
$700.00M
株価収益率:
2.6521
EPS:
2.6922
ネットキャッシュフロー:
$537.00M
1週間 パフォーマンス:
-7.75%
1か月 パフォーマンス:
+9.51%
6か月 パフォーマンス:
-25.08%
1年 パフォーマンス:
-53.52%
1日の値動き範囲:
$7.09
$7.32
1週間の範囲:
$7.09
$7.85
52週間の値動き範囲:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
OGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.14 | 1.89B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,014.49 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.71 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.43 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Can Organon (OGN) Turn Rising Investor Attention Into a Durable Reboot of Its Core Story? - simplywall.st
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Co. (7XP) stock compared to peersPortfolio Update Report & Precise Buy Zone Identification - Newser
Organon & Co. $OGN Shares Acquired by Brandes Investment Partners LP - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Russell Investments Group Ltd. Has $15.96 Million Stock Position in Organon & Co. $OGN - MarketBeat
Can Organon’s (OGN) Biosimilar Push Transform Its Competitive Position in US Oncology? - Yahoo Finance UK
A Look at Organon's Valuation Following FDA Approval of First US Pertuzumab Biosimilar - Yahoo Finance UK
What analysts say about Organon Co 7XP stockShort Interest Overview & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? - The Globe and Mail
Grantham Mayo Van Otterloo & Co. LLC Buys 108,429 Shares of Organon & Co. $OGN - MarketBeat
Avoiding Lag: Real-Time Signals in (OGN) Movement - news.stocktradersdaily.com
Organon (OGN): Exploring Valuation Following FDA Approval of First US Pertuzumab Biosimilar - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Is Organon Co 7XP a good long term investmentLong-Term Investment Plans & High Yield Investment Portfolio - earlytimes.in
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks - The Globe and Mail
EXTENDED CLASS PERIOD: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire) - Aktiellt
TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire) - Aktiellt
Congressional Trading Report: Sen. Gary C Peters Sold Over $1K In Organon Stock - Benzinga
Organon (NYSE: OGN) leaders to speak at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Organon & Co.Gary C. Peters Congressional Trade on Jul. 10, 2025 - Quiver Quantitative
Organon’s Deep Discount Comes With a Heavy Dose of Risk - Finimize
Can OGN’s First US Biosimilar Approval Redefine Its Long-Term Oncology Strategy? - Sahm
Organon and QC LGU empower women to ‘Take Control’ on World Contraception Day - Inquirer.net
Organon announces departure of chief commercial officer - MSN
Co. (7XP) stock profit from AI boomChart Signals & Consistent Profit Alerts - newser.com
Discipline and Rules-Based Execution in OGN Response - news.stocktradersdaily.com
Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld MedTech
Co. (7XP) stock profit from automation waveWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
Organon Executive Chairman of the Board Acquires 525% More Stock - simplywall.st
[Form 4] Organon & Co. Insider Trading Activity - Stock Titan
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - Yahoo Finance
Henlius and Organon score first US Perjeta biosimilar approval - Yahoo Finance
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight - GlobeNewswire Inc.
Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar - MarketScreener
Organon announces FDA approval for Poherdy BLA - TipRanks
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call - The Globe and Mail
(pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US - Business Wire
The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call - Finviz
Organon Q3 2025 Earnings: Revenue & EPS Beat EstimatesNews and Statistics - IndexBox
Organon (OGN) Price Target Decreased by 10.77% to 9.86 - Nasdaq
Are Margin Pressures Reshaping Organon’s (OGN) Long-Term Competitive Position? - simplywall.st
Organon & Co. (OGN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - Business Wire
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67 - simplywall.st
Executive Chairman of the Board of Organon Carrie Cox Buys 525% More Shares - Yahoo Finance
First Perjeta Biosimilar Is Approved In The US For Henlius And Organon - Citeline News & Insights
Executive Chair Makes Bold Move with Major Organon Stock Purchase - TipRanks
Organon Shares Face Mounting Pressure Amid Strategic Shifts - AD HOC NEWS
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
0.51%
大文字化:
|
ボリューム (24 時間):